BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ...
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ...
Larimar (LRMR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results